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A B S T R A C T
IL-37 is a member of the IL-1 family, but unlike most other members of this family of cytokines, it has wide-
ranging anti-inﬂammatory properties. Initially shown to bind IL-18 binding protein and prevent IL-18-mediated
inﬂammation, its known role has been expanded to include distinct pathways, both intracellular involving the
transcription factor Smad3, and extracellular via binding to the orphan receptor IL-1R8. A number of recent
publications investigating the role of IL-37 in atherosclerosis and ischemic heart disease have revealed promising
therapeutic value of the cytokine. Although research concerning the role of IL-37 and its mechanism in ather-
osclerosis is relatively scant, there are a number of well-known atherosclerotic processes that this cytokine can
mediate with the potential of modulating the disease progression itself. This review will probe in detail the
eﬀects of IL-37 on important pathological processes such as inﬂammation, dysregulated lipid metabolism, and
apoptosis, by analyzing existing data as well as exploring the potential of this cytokine to inﬂuence these
properties.
1. Introduction
Since its discovery in 2000 by in silico research, the Interleukin (IL)-
1 family cytokine IL-37 has gained much attention due to its potent
anti-inﬂammatory properties. Initially shown to prevent IL-18-induced
inﬂammation via binding to the IL-18 binding protein (IL-18bp), the
mechanisms by which IL-37 functions have been further elucidated in
the last few years to include both intra- and extra-cellular pathways
involving the transcription factor Smad3 and the orphan receptor IL-
1R8, respectively. There are 5 known splice variants of IL-37, desig-
nated a-e [1]. The longest isoform, IL-37b, is predominantly found in
immune cells, and is the most well characterized to date [2].
Notably, there is no known mouse homolog of human IL-37.
However, a landmark 2010 publication by Nold et al. [3] showed that
transgenic mice expressing human IL-37b are protected from acute in-
ﬂammation. The ﬁnding that human IL-37 is functional in the mouse
has paved the way for many studies using mouse models to investigate
the role of IL-37 in a wide range of inﬂammatory diseases. It is worth
noting that IL-37 does exist in many other rodents such as Guinea pigs
and rabbits [4], which could be used to develop a knockout model for
studying IL-37 deﬁciency in vivo.
Many correlation studies using human samples have shown a strong
connection between IL-37 levels and various disease states. IL-37 ex-
pression has been strongly associated with many inﬂammatory dis-
eases, both autoimmune [5–9], and infection-related [10,11]. Elevated
plasma IL-37 levels have also been found in human patients with acute
coronary syndrome [12] and atrial ﬁbrillation [13]. Research using
mouse models of pathogenic cardiovascular inﬂammation, including
ischemia/reperfusion (I/R) injury [14,15], myocardial infarction (MI)
[16,17], and vascular calciﬁcation [18,19], reveal signiﬁcant beneﬁt
from IL-37 expression or treatment in vivo, indicating promising ther-
apeutic value for use of the cytokine to treat the equivalent conditions
in humans. Here we review the potential role of IL-37 in cardiovascular
disease, with a speciﬁc focus on its protective eﬀects against athero-
sclerosis development.
2. IL-37 modulates multiple atherogenic macrophage functions
The initiation of atherosclerosis occurs when circulating LDL par-
ticles become trapped within the arterial wall and become modiﬁed,
eliciting an inﬂammatory response. Signaling molecules produced by
cells of the vessel wall, such as endothelial cells and smooth muscle
cells, lead to activation of the innate immune response. Although the
role of IL-37 has been examined in various inﬂammatory diseases of
both acute and chronic nature, there is limited research on the ther-
apeutic potential of IL-37 to reduce the chronic inﬂammation and
dysregulated cholesterol homeostasis that drive the pathogenesis of
atherosclerosis. However, the known protective eﬀects of IL-37 on the
various cell types involved in atherogenesis, especially macrophages,
suggest a therapeutic role for the cytokine in preventing or suppressing
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